Bausch & Lomb eyes up VISX's payment and patent rights
This article was originally published in Clinica
Bausch & Lomb is still not commenting on whether it plans to fall in line with VISX's payment per procedure strategy in the US or to challenge that company's patent position by not passing on fees when its Technolas 217 laser for LASIK procedures is launched at the end of the year. VISX at present claims a $250 fee per use for excimer laser photorefractive surgery procedures carried out in the US that are covered by one or more of its many patents in this area.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.